Systematic Analysis of Splice-Site-Creating Mutations in Cancer

Cell Rep. 2018 Apr 3;23(1):270-281.e3. doi: 10.1016/j.celrep.2018.03.052.

Abstract

For the past decade, cancer genomic studies have focused on mutations leading to splice-site disruption, overlooking those having splice-creating potential. Here, we applied a bioinformatic tool, MiSplice, for the large-scale discovery of splice-site-creating mutations (SCMs) across 8,656 TCGA tumors. We report 1,964 originally mis-annotated mutations having clear evidence of creating alternative splice junctions. TP53 and GATA3 have 26 and 18 SCMs, respectively, and ATRX has 5 from lower-grade gliomas. Mutations in 11 genes, including PARP1, BRCA1, and BAP1, were experimentally validated for splice-site-creating function. Notably, we found that neoantigens induced by SCMs are likely several folds more immunogenic compared to missense mutations, exemplified by the recurrent GATA3 SCM. Further, high expression of PD-1 and PD-L1 was observed in tumors with SCMs, suggesting candidates for immune blockade therapy. Our work highlights the importance of integrating DNA and RNA data for understanding the functional and the clinical implications of mutations in human diseases.

Keywords: RNA; mutations of clinical relevance; splicing.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • BRCA1 Protein / genetics
  • GATA3 Transcription Factor / genetics
  • HEK293 Cells
  • Humans
  • Mutation*
  • Neoplasms / genetics*
  • Poly (ADP-Ribose) Polymerase-1 / genetics
  • Programmed Cell Death 1 Receptor / genetics
  • RNA Splice Sites*
  • Tumor Suppressor Protein p53 / genetics
  • X-linked Nuclear Protein / genetics

Substances

  • BRCA1 Protein
  • BRCA1 protein, human
  • GATA3 Transcription Factor
  • GATA3 protein, human
  • Programmed Cell Death 1 Receptor
  • RNA Splice Sites
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • PARP1 protein, human
  • Poly (ADP-Ribose) Polymerase-1
  • ATRX protein, human
  • X-linked Nuclear Protein